[go: up one dir, main page]

WO2003101386A3 - Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis - Google Patents

Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis Download PDF

Info

Publication number
WO2003101386A3
WO2003101386A3 PCT/US2003/016961 US0316961W WO03101386A3 WO 2003101386 A3 WO2003101386 A3 WO 2003101386A3 US 0316961 W US0316961 W US 0316961W WO 03101386 A3 WO03101386 A3 WO 03101386A3
Authority
WO
WIPO (PCT)
Prior art keywords
ras
ksr
therapy
expression
inactivation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/016961
Other languages
French (fr)
Other versions
WO2003101386A2 (en
Inventor
Richard N Kolesnick
Hongmei R Xing
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2003238804A priority Critical patent/AU2003238804A1/en
Priority to JP2004508744A priority patent/JP4646625B2/en
Priority to DE60333365T priority patent/DE60333365D1/en
Priority to EP03734263A priority patent/EP1513859B1/en
Priority to AT03734263T priority patent/ATE474045T1/en
Priority to CA002488048A priority patent/CA2488048A1/en
Priority to US10/516,342 priority patent/US7528116B2/en
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Priority to US10/727,358 priority patent/US7301017B2/en
Publication of WO2003101386A2 publication Critical patent/WO2003101386A2/en
Publication of WO2003101386A3 publication Critical patent/WO2003101386A3/en
Anticipated expiration legal-status Critical
Priority to US11/974,481 priority patent/US8283459B2/en
Priority to US11/974,473 priority patent/US8258108B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Environmental Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Animal Husbandry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to methods and compositions for the specific inhibition of kinase suppressor of Ras (KSR). In particular, the invention provides genetic approaches and nucleic acids for the specific inhibition of KSR, particularly of KSR expression. The invention relates to antisense oligonucleotides and the expression of nucleic acid which is substantially complementary to KSR RNA. Oligonucleotide and nucleic acid compositions are provided. The invention provides methods to inhibit KSR, including inhibition of KSR expression. Methods for blocking gf Ras mediated tumorigenesis, metastasis, and for cancer therapy are provided.
PCT/US2003/016961 2002-05-30 2003-05-29 Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis Ceased WO2003101386A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
US10/516,342 US7528116B2 (en) 2002-05-30 2003-05-29 Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis
DE60333365T DE60333365D1 (en) 2002-05-30 2003-05-29 KINASESUPPRESSOR OF RAS INACTIVATION FOR THE THERAPY OF RAS-ASSOCIATED TUMORGENESIS
EP03734263A EP1513859B1 (en) 2002-05-30 2003-05-29 Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis
AT03734263T ATE474045T1 (en) 2002-05-30 2003-05-29 KINASE SUPPRESSOR OF RAS INACTIVATION FOR THE THERAPY OF RAS-MEDIATED TUMORGENESIS
CA002488048A CA2488048A1 (en) 2002-05-30 2003-05-29 Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis
AU2003238804A AU2003238804A1 (en) 2002-05-30 2003-05-29 Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis
JP2004508744A JP4646625B2 (en) 2002-05-30 2003-05-29 Ras inactivated kinase suppressor for the treatment of Ras mediated tumorigenesis
US10/727,358 US7301017B2 (en) 2002-05-30 2003-12-03 Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis
US11/974,473 US8258108B2 (en) 2002-05-30 2007-10-12 Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis
US11/974,481 US8283459B2 (en) 2002-05-30 2007-10-12 Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38422802P 2002-05-30 2002-05-30
US60/384,228 2002-05-30
US46002303P 2003-04-03 2003-04-03
US60/460,023 2003-04-03

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/727,358 Continuation-In-Part US7301017B2 (en) 2002-05-30 2003-12-03 Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis
US11/974,481 Continuation-In-Part US8283459B2 (en) 2002-05-30 2007-10-12 Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis

Publications (2)

Publication Number Publication Date
WO2003101386A2 WO2003101386A2 (en) 2003-12-11
WO2003101386A3 true WO2003101386A3 (en) 2004-10-07

Family

ID=29715317

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/016961 Ceased WO2003101386A2 (en) 2002-05-30 2003-05-29 Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis

Country Status (8)

Country Link
US (1) US7528116B2 (en)
EP (1) EP1513859B1 (en)
JP (1) JP4646625B2 (en)
AT (1) ATE474045T1 (en)
AU (1) AU2003238804A1 (en)
CA (1) CA2488048A1 (en)
DE (1) DE60333365D1 (en)
WO (1) WO2003101386A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301017B2 (en) * 2002-05-30 2007-11-27 Kolesnick Richard N Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis
WO2006138145A1 (en) 2005-06-14 2006-12-28 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
JP5512285B2 (en) 2007-02-09 2014-06-04 ノースウェスタン ユニバーシティ Particles for detecting intracellular targets
DK2160464T3 (en) 2007-05-30 2014-08-04 Univ Northwestern NUCLEIC ACID FUNCTIONALIZED NANOPARTICLES FOR THERAPEUTIC APPLICATIONS
WO2009076598A1 (en) 2007-12-12 2009-06-18 Children's Hospital & Research Center At Oakland Use of unsaturated sphingosine compounds as chemotherapeutic agents for the treatment of cancer
US8895701B2 (en) 2008-01-05 2014-11-25 Sloan-Kettering Institute For Cancer Research Peptide-conjugated oligonucleotide therapeutic and method of making and using same
EP2365803B1 (en) 2008-11-24 2017-11-01 Northwestern University Polyvalent rna-nanoparticle compositions
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
KR20170072367A (en) * 2009-04-15 2017-06-26 노오쓰웨스턴 유니버시티 Delivery of oligonucleotide-functionalized nanoparticles
WO2011009218A1 (en) * 2009-07-24 2011-01-27 Université de Montréal Raf dimers and uses thereof
US9376690B2 (en) 2009-10-30 2016-06-28 Northwestern University Templated nanoconjugates
WO2012083249A2 (en) 2010-12-17 2012-06-21 The Trustees Of Columbia University In The City Of New York Dna sequencing by synthesis using modified nucleotides and nanopore detection
CN104023749B (en) 2011-09-14 2019-12-17 西北大学 Nanoconjugates capable of crossing the blood-brain barrier
CA2869753A1 (en) 2012-04-09 2013-10-17 Jingyue Ju Method of preparation of nanopore and uses thereof
WO2015187966A1 (en) 2014-06-04 2015-12-10 Aurasense Therapeutics, Llc Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
US12264344B2 (en) 2014-08-19 2025-04-01 Northwestern University Protein/oligonucleotide core-shell nanoparticle therapeutics
CN107106493A (en) 2014-11-21 2017-08-29 西北大学 The sequence-specific cellular uptake of spherical nucleic acid nano particle conjugate
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021820A2 (en) * 1995-12-13 1997-06-19 The Regents Of The University Of California A novel protein kinase required for ras signal transduction

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5218105A (en) 1990-07-27 1993-06-08 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
US5591721A (en) 1994-10-25 1997-01-07 Hybridon, Inc. Method of down-regulating gene expression
GB9620749D0 (en) 1996-10-04 1996-11-20 Brax Genomics Ltd Identifying antisense oligonucleotides
WO1999001139A1 (en) * 1997-07-03 1999-01-14 Thomas Jefferson University An improved method for design and selection of efficacious antisense oligonucleotides
GB2335035B (en) 1998-03-03 2003-05-28 Brax Genomics Ltd Screening for functional antisense agents
US6310047B1 (en) 1999-08-24 2001-10-30 Virginia Commonwealth University High affinity DNA binding compounds as adjuvants in antisense technology
US20030051267A1 (en) * 2001-05-10 2003-03-13 Pfizer Inc. Targeted disruption of kinase suppressor of RAS
US20030109466A1 (en) * 2001-09-20 2003-06-12 Isis Pharmaceuticals Inc. Antisense modulation of KSR expression

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021820A2 (en) * 1995-12-13 1997-06-19 The Regents Of The University Of California A novel protein kinase required for ras signal transduction

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROJANASAKUL Y.: "ANTISENSE OLIGONUCLEOTIDE THERAPEUTICS: DRUG DELIVERY AND TARGETING", ADVANCED DRUG DELIVERY REVIEWS, vol. 18, 1996, pages 115 - 131, XP002913878 *

Also Published As

Publication number Publication date
US7528116B2 (en) 2009-05-05
EP1513859B1 (en) 2010-07-14
WO2003101386A2 (en) 2003-12-11
ATE474045T1 (en) 2010-07-15
EP1513859A2 (en) 2005-03-16
CA2488048A1 (en) 2003-12-11
JP4646625B2 (en) 2011-03-09
EP1513859A4 (en) 2007-11-14
AU2003238804A1 (en) 2003-12-19
DE60333365D1 (en) 2010-08-26
US20060252037A1 (en) 2006-11-09
JP2005534295A (en) 2005-11-17
AU2003238804A8 (en) 2003-12-19

Similar Documents

Publication Publication Date Title
WO2003101386A3 (en) Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis
WO2002026967A3 (en) Targeted gene correction by single-stranded oligodeoxynucleotides
WO2006047842A3 (en) Modified nucleosides for rna interference
AU2003210895A8 (en) Rna interference mediated inhibition of cyclin d1 gene expression using short interfering nucleic acid (sina)
AU4595399A (en) Antisense oligonucleotide constructs based on beta-arabinofuranose and its analogues
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
WO2003048315A3 (en) Antisense modulation of mdm2 expression
AU2003213054A8 (en) Rna interference mediated inhibition of polycomb group protein ezh2 gene expression using short interfering nucleic acid (sina)
WO2005056756A3 (en) Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis
WO2007044468A3 (en) Method to treat flavivirus infection with sirna
AU2003219833A8 (en) Rna interference mediated inhibition of chromosome translocation gene expression using short interfering nucleic acid (sina)
WO2004001013A3 (en) Inhibition of gene expression in vertebrates using double-stranded rna (rnai)
AU8944801A (en) Chimeric antisense of arabinofuranose analogue and deoxyribose nucleotides
WO2007117121A3 (en) Gene therapy for cancer using small interfering rna specific to ant2 and a method to overcome tolerance to antitumor agent
WO2005042705A3 (en) Short interfering rna and micro-rna compounds and methods of designing, making and using the same
WO2005112636A3 (en) COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF PRIMATE POLYOMAVIRUS GENES
WO2001083513A3 (en) Antisense modulation of inhibitor of dna binding-1 expression
WO2004104199A3 (en) Modulation of gene expression using dna-dna hybrids
AU2003215161A1 (en) RNA INTERFERENCE MEDIATED INHIBITION OF TELOMERASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2003035667A3 (en) Telomerase interference
GB2406568B (en) RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
MXPA05008329A (en) Use of a novel polymorphism in the hsgk1 gene in the diagnosis of hypertonia and use of the sgk gene family in the diagnosis and therapy of the long qt syndrome.
EP1322658A4 (en) OLIGONUCLEOTIDE MODULATION OF HER-1 EXPRESSION
WO2008015577A3 (en) Sensizitation of cancer cells to therapy using sina targeting genes from the 1p and 19q chromosomal regions
WO2005019433A3 (en) VIRALLY-ENCODED RNAs AS SUBSTRATES, INHIBITORS AND DELIVERY VEHICLES FOR RNAi

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 10727358

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2488048

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004508744

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003734263

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003734263

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006252037

Country of ref document: US

Ref document number: 10516342

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10516342

Country of ref document: US